New York, USA, May 06, 2024 (GLOBE NEWSWIRE) -- Global Liver Disease Therapeutics Market to Grow Rapidly by 2030, Examines DelveInsight | Key Players in the Market - AbbVie, GSK, F.Hoffmann-La Roche, Bristol-Myers Squibb Company, Abbott, Gilead Sciences, Astellas Pharma  The surge in liver disease therapeutics demand stems mainly from a growing population afflicted with liver ailments, elevated alcohol intake, and unhealthy dietary patterns, among other factors.

2024年5月6日，美国纽约（环球通讯社）--到2030年，全球肝病治疗市场将迅速增长，DelveInsight考察了市场上的主要参与者-艾伯维（AbbVie）、葛兰素史克（GSK）、F.Hoffmann-La Roche、百时美施贵宝（Bristol-Myers Squibb Company）、雅培（Abbott）、吉利德科学（Gilead Sciences）、阿斯特拉斯制药（Astellas Pharma）。肝病治疗药物需求的激增主要源于越来越多的肝病患者、酒精摄入量增加和不健康的饮食模式等因素。

Additionally, the liver disease therapeutics market is poised for expansion due to numerous ongoing research endeavors, alliances among healthcare entities, researchers, and industry stakeholders, as well as strategic collaborations.  DelveInsight’s Liver Disease Therapeutics Market Insights report provides the current and forecast market analysis, individual leading liver disease therapeutics companies’ market shares, challenges, liver disease therapeutics market drivers, barriers, trends, and key market liver disease therapeutics companies in the market.

此外，由于许多正在进行的研究工作，医疗保健实体，研究人员和行业利益相关者之间的联盟以及战略合作，肝病治疗市场有望扩大。DelveInsight的肝病治疗市场洞察报告提供了当前和预测市场分析，个别领先肝病治疗公司的市场份额，挑战，肝病治疗市场驱动因素，障碍，趋势以及市场上主要的肝病治疗公司。

Key Takeaways from the Liver Disease Therapeutics Market Report As per DelveInsight estimates, North America is anticipated to dominate the global liver disease therapeutics market during the forecast period. Notable liver disease therapeutics companies such as AbbVie Inc., GSK, F.Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Abbott, Gilead Sciences, Inc., Astellas Pharma Inc., Merck & Co., Inc., Alnylam Pharmaceuticals, Inc., Sanofi, GSK plc, and several others, are currently operating in the liver disease therapeutics market.On March 14, 2024, the FDA greenlit Madrigal Pharmaceuticals’ REZDIFFRA (resmetirom) for treating NASH, in cases of moderate to severe liver scarring, or fibrosis, at stages F2 and F3.In January 2024, Suzhou Ribo Life Science C.

肝病治疗市场报告的主要收获根据DelveInsight的估计，预计在预测期内，北美将主导全球肝病治疗市场。著名的肝病治疗公司，如AbbVie Inc.，GSK，F.Hoffmann-La Roche Ltd.，Bristol-Myers Squibb Company，Abbott，Gilead Sciences，Inc.，Astellas Pharma Inc.，Merck＆Co.，Inc.，Alnylam Pharmaceuticals，Inc.，Sanofi，GSK plc等，目前正在肝病治疗市场运营。2024年3月14日，FDA greenlit Madrigal Pharmaceuticals的REZDIFFRA（resmetirom）在F2和F3期治疗中度至重度肝瘢痕或纤维化的NASH。2024年1月，苏州Ribo Life Science C。